Advanced diagnostics, redefined
As the only hospital reference lab integrated with a world-renowned academic healthcare institution, Mayo Clinic Laboratories fuses diagnostic testing innovation with a 150-year history of patient-focused care. In that tradition, we advocate for delivering care as close to the patient as possible, offering a vast menu of esoteric and advanced assays that complements, rather than competes with, local care delivery.
Our proactive consultative approach helps hospital laboratories uncover their financial potential and improve profitability while keeping patient care as the focus. Through synergistic relationships, we equip lab teams and hospital executives with tailored tools and strategies to expand laboratory capabilities and improve efficiencies. This supports the growth of the lab, and the health system, into new areas of diagnostic care.
“Our business model and our mission are to support the local care of patients. We work with hospitals and hospital laboratories to help them insource testing they should to take care of their patients, and give them access to those more uncommon tests we're developing within our practice.”
William Morice II, M.D., Ph.D., President and CEO, Mayo Clinic Laboratories
Our difference
News and updates
The latest
An order-entry, clinical decision support tool developed by physicians and scientists at Froedtert and the Medical College of Wisconsin (MCW) for clinicians within the healthcare system who order autoimmune and paraneoplastic antibody panels has significantly improved test utilization, resulting in a 28% reduction in monthly test volumes of impacted tests.
As chair of Mayo Clinic’s new Division of Computational Pathology and AI in the Department of Laboratory Medicine and Pathology, Jason Hipp, M.D., Ph.D., is eager to employ the most innovative tools available to benefit patients around the globe.
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.
October 26, 2021 On September 27-28, 2021, Mayo Clinic Laboratories held its 32nd Leveraging the Laboratory conference, virtually. Attendees gave resounding positive feedback regarding content[...]
In a newly published study, a team from Mayo Clinic’s Advanced Diagnostics Laboratory has developed a mass spectrometry-based assay that’s able to detect COVID-19 (SARS-CoV-2) pathogens from human proteins with, remarkably, 98% sensitivity and 100% specificity. This is the first assay of its kind that can detect viral antigens “directly from clinical specimens” such as nasopharyngeal swabs. Mass spectrometry is a sensitive technique used to detect, identify, and quantitate molecules present in a sample.
Dan O’Bryan didn’t think his dizziness and lightheadedness were anything to worry about. Nearly 100 miles away, the team at Mayo Clinic that was remotely monitoring Dan’s heart could see the truth.
Personalized medicine represents unprecedented potential benefits for patients. LabConnect and Mayo Clinic BioPharma Diagnostics are working together to bring world-class laboratory testing and resources to industry partners conducting clinical research and trials.
Before testing at Mayo Clinic Laboratories, Barbara Domaille, Deborah Neville, Pamela Neville, and Rylie Ronnenberg thought there could be a genetic connection to the hip problems they shared. After the testing, they knew for sure.
A web of innovation within Mayo Clinic Laboratories links research and test development with clinical practice, enabling for some of the world’s most pioneering methodologies. Underpinning this innovation network are unique supports that provide inventive and essential solutions to broaden testing capabilities.
It’s been understood for some time that an infection of B. mayonii, a rare species of bacterium, results in high levels of spirochetes in the peripheral blood. But actually being able to visualize them on a routine peripheral blood smear may allow for improved recognition of this uncommon cause of Lyme disease.
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about 10% of MN patients and is linked to underlying malignancy.
Delta Health leveraged their relationship with Mayo Clinic Laboratories to support patient in rural Colorado during the COVID-19 pandemic. Delta Health and Mayo Clinic Laboratories have collaborated for over 17 years to perform complex and esoteric testing.
The genetic variability of glioma, and its more advanced relative glioblastoma, has made genetic testing to identify biomarkers associated with prognosis and treatment effectivity an integral component of care plan development. However, the acceleration of brain tumor research and discovery translates into an ever-changing testing environment.